## BACHNER, TALLY, POLEVOY & MISHER

ROBERT L. BACHNER
HENRY J. BERGMAN
KENNETH P. CARROLL
JILL M. COHEN
ROBERT H. COHEN
ROGER R. CRANE, JR.
RICHARD S. FRIES
SAM W. GALOWITZ
PAUL E. GELBARD\*
JONATHAN M. HARRIS

JILL HAYMAN A
ALAN E. LINDER
SHELDON E. MISHER
BENJAMIN NEWMAN
ANDREW T. NICHOLS\*A
H. RICHARD PENN
DONALD P. PERRY
MARTIN D. POLEVOY
CHARLES B. SALFELD
PAUL H. SILVERMAN

MARC HUREL

LINA LIBERATORE

MICHAEL P. MANNING

LAWRENCE W. RADER

SONYA LORGE A

IRA J. LAST

ATTORNEYS AT LAW
380 MADISON AVENUE
NEW YORK, NEW YORK 10017-2590
(212) 687-7000

FAX: (212) 682-5729

LESTER R. BACHNER (1918-1976) CHARLES H. TALLY (1936-1987)

COUNSEL

JACK A. HORN <sup>95</sup>

LINDA R. LEBENSOLD

NORMAN MARCUS

OF COUNSEL SIMEON BRINBERG

FLORIDA OFFICE 2101 WEST COMMERCIAL BOULEVARD SUITE 5300 FORT LAUDERDALE, FLORIDA 33309 (305) 486-7600

> SEYMOUR L. MANTELL GERALD BEYER RESIDENT PARTNERS

September 24, 1990

MARIANNE M. ACITO
BETH S. BARASH
JEFFREY A. BAUMEL A
ADAM B. BAYROFF A
ALEXANDER BIENENSTOCK
J. GOODWIN BLAND
CARYN J. BLOCK\*
BRUCE M. BROOKOFF
GERARD S. DIFIORE A
MONICA S. GROSSBAUM

\*ALSO ADMITTED IN FL

ALSO ADMITTED IN IL

CARYN J. BLOCK\*

BRUCE M. BROOKOFF
GERARD S. DIFIORE†

MONICA S. GROSSBAUM
CHERYL J. HAUK°

\*\*ALSO ADMITTED IN CT

MARIA E. RUSSO\*
FRAN M. STALLARD
FRAN M. STOLLER
JONNIE STRONG\*

TALSO ADMITTED IN MA
ALSO ADMITTED IN NJ
LISO ADMITTED IN WASH, D. C.

## VIA MESSENGER

Richard A. Jaffe, Esq. Abady & Jaffe 500 Fifth Avenue 24th Floor New York, New York 10110

Re: Elan/Burzynski

Dear Richard:

After its continued due diligence investigation and receipt of your comments on the proposed agreements between Elan and Burzynski, Elan has determined that it is not in its best interest to enter into a license or supply agreement with Dr. Burzynski or the Burzynski Research Institute. As we have discussed before, Elan has significant doubt as to whether the active substances comprising AS 2-1 have patent protection, thereby rendering an exclusive license and supply agreement meaningless. As Dr. Burzynski's representation that the licensed products are included in a patent owned by him or the Institute was, of course, integral to the proposed license and relied on by Elan in entering into the letter of intent, the lack of patent coverage clearly constitutes a material misrepresentation by Dr. Burzynski. In view of this misrepresentation, Elan is entitled to a full refund of the \$150,000 advance of the license issue fee paid by it upon the signing of the letter of intent, which should be forwarded directly to Elan upon receipt of this letter.

Very truly yours,

JMC:brf

cc: Stanislaw Burzynski, M.D.